This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Efficacy

Only SHINGRIX delivered >90% efficacy against shingles regardless of age in those 50 years and older1,*,

AGE EFFICACY
(95% CI)
SHINGLES CASES
(n) IN SHINGRIX
GROUP (N)
SHINGLES CASES
(n) IN PLACEBO
GROUP (N)
50-59*

96.6%

(89.6, 99.3)

3
(3492)
87
(3525)
60-69*

97.4%

(90.1, 99.7)

2
(2141)
75
(2166)
70-79

91.3%

(86.0, 94.9)

19
(6468)
216
(6554)
≥80

91.4%

(80.2, 96.9)

6
(1782)
68
(1792)
  •   *Data from ZOE-50 phase 3 trial.1,3
  •   Pooled data from ZOE-50 and ZOE-70 phase 3 trials.1,2


CI=confidence interval.
HZ=herpes zoster.
n=number of subjects having at least 1 confirmed HZ episode.
N=number of subjects in each group.
PHN=postherpetic neuralgia.

Study 1 Design: Data from ZOE-50—a placebo-controlled, observer-blind phase 3 trial conducted in 18 countries in which subjects ≥50 years old were randomized to receive 2 doses (0 and 2 months) of either SHINGRIX (N=7698) or placebo (N=7713). A total of 7344 and 7415 subjects who received SHINGRIX and placebo, respectively, were included in the modified Total Vaccinated Cohort (mTVC) analysis.1,3

Study 2 Design: Data from ZOE-70—a placebo-controlled, observer-blind phase 3 trial conducted in 18 countries in which subjects ≥70 years old were randomized to receive 2 doses (0 and 2 months) of either SHINGRIX (N=6950) or placebo (N=6950). A total of 6541 and 6622 subjects who received SHINGRIX and placebo, respectively, were included in the mTVC analysis.1,2

The primary efficacy analysis (mTVC) in Studies 1 and 2 included all subjects who did not develop a confirmed case of HZ within 1 month after the second dose.1

Pooled Analysis: Data from ZOE-50 and ZOE-70 were combined in a prespecified pooled analysis. A total of 8250 and 8346 subjects ≥70 years of age who received SHINGRIX and placebo, respectively, were included.1

The studies excluded subjects who were immunocompromised, had a previous history of HZ, were previously vaccinated against varicella or HZ, and patients whose survival was not expected to be at least 4 years, or with conditions that might interfere with study evaluations.1
 

You may also be interested in:

Learn about the results of two phase 3 clinical trials in which adverse reactions to SHINGRIX were studied.

Learn how age-related decline in immunity is a dominant driver of shingles and can lead to a sharp increase in both the incidence and complications of shingles.4-6

See what CDC says about SHINGRIX.

CDC=Centers for Disease Control and Prevention.

References: 1. Prescribing Information for SHINGRIX. 2. Cunningham AL, Lal H, Kovac M, et al, for the ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019-1032. 3. Lal H, Cunningham AL, Godeaux O, et al, for the ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087-2096. 4. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500. 5. Centers for Disease Control and Prevention. Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 6. Kimberlin DW, Whitley RJ. Varicella–zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007;356(13):1338-1343.

Trademarks are property of their respective owners.